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Abstract: The potential of marine benthic cyanobacteria as a source of anticancer drug 
candidates was assessed in a screen for induction of cell death (apoptosis) in acute myeloid 
leukemia (AML) cells. Of the 41 marine cyanobacterial strains screened, more than half 
contained cell death-inducing activity. Several strains contained activity against AML cells, 
but not against non-malignant cells like hepatocytes and cardiomyoblasts. The apoptotic 
cell death induced by the various strains could be distinguished by the role of caspase 
activation  and  sensitivity  to  the  recently  detected  chemotherapy-resistance-associated 
prosurvival  protein LEDGF/p75.  One strain  (M44) was  particularly promising since its 
activity  counteracted  the  protective  effect  of  LEDGF/p75  overexpressed  in  AML cells, 
acted synergistically with the anthracycline anticancer drug daunorubicin in AML cells, and 
protected  cardiomyoblasts  against  the  toxic  effect  of  anthracyclines.  We  conclude  that 
culturable benthic marine cyanobacteria from temperate environments provide a promising 
and hitherto underexploited source for novel antileukemic drugs.  
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1. Introduction 
Marine cyanobacteria have been recognized as a source for new drugs and drug leads [1,2]. For 
instance, clinical anticancer trials are being conducted with soblidotin (TZT-1027) and synthadotin 
(ILX-651), two derivatives of dolastatin 10 isolated from the benthic tropical marine cyanobacteria 
Symploca sp. [3,4]. In addition, derivatives of curacin A isolated from the benthic tropical marine 
cyanobacteria Lyngbya majuscula are in preclinical trials for treatment of cancer [5]. Most cytotoxic 
marine cyanobacterial compounds have been isolated from tropical benthic Lyngbya sp. and Symploca 
sp. forming large mats, whereas only a few cytotoxic compounds have been reported from other marine 
genera  [1,2,6].  Less  studied  marine  cyanobacteria  genera  should  therefore  be  included  in  
anticancer screens.  
Acute myeloid leukemia (AML) is the second most common form of leukemia [7]. Treatment of 
AML  consists  mainly  of  chemotherapy  using  cytosine  arabinoside  (Ara-C)  and  the  anthracycline 
daunorubicin  [8].  Chemoresistant  disease,  either  as  primary  resistance  to  induction  therapy  or  as 
relapse  due  to  resistant  residual  disease,  is  the  major  cause  of  treatment  failure  in  most  cancers, 
including  AML  [9,10].  There  are  several  recently  discovered  factors  involved in  chemoresistance. 
Increased  expression  of  the  transcriptional  co-activator  Lens  Epithelium-Derived  Growth  Factor 
LEDGF/p75 has been reported in chemotherapy-resistant human AML blasts as well as in breast and 
bladder carcinomas [11–13]. Another anti-apoptotic protein that confers chemotherapy resistance to 
AML cells, and is associated with a poor therapeutic prognosis, is Bcl-2 [14,15]. There is a need for 
new  therapies  in  treatment  of  AML,  since  if  standard therapy fails  there is  usually no alternative 
treatment [9,10]. New therapies are also needed for other types of cancer, and drugs used to treat 
leukemia have often been transferred to other cancers with little or no modifications, as exemplified by 
the anthracyclines [16]. 
We have previously shown that cyanobacteria constitute a rich source of bioactivities [17–21], and 
wanted to investigate if culturable marine benthic cyanobacteria from temperate environments were 
potential producers of compounds with anticancer potential. We investigated strains sampled from the 
shores of the Baltic Sea and found that a high proportion of these induced cell death in AML cells. 
Three strains were able to induce apoptosis in chemoresistant AML cells with enforced expression of 
LEDGF/p75, whereas non-malignant cells remained viable. In combination with daunorubicin these 
three  anti-AML  activities  induced  an  apoptotic  synergistic  response  in  leukemia  cells,  but  not  in 
cardiomyoblasts. 
2. Results 
2.1. Screening of benthic marine cyanobacteria for leukemia cell death inducers 
Forty-one benthic Baltic Sea cyanobacterial strains of the genera Anabaena, Nostoc, Calothrix and 




hepatocytes  [17],  were  extracted  sequentially  with  water,  aqueous  70%  methanol,  and  1:1 
methanol:dichloromethane  (A,  B  and  C  extracts,  respectively).  They  were  first  screened  for  cell  
death-inducing activity against the AML cell line IPC-81wt [22], which originates from the BNML rat 
model, known to  be a reliable predictor of the outcome of anticancer treatment  [23]. Nineteen A 
extracts, 13 B extracts, and 6 C extracts contained cell death inducers. Ten strains (M4, 8, 9, 11, 12, 13, 
23, 26, 33, 37) contained cell death inducing activity in more than one extract, like strain M26 that 
contained activity in the A and C extract, but not in the intermediate B extract (Figure 1). Several of the 
extracts with anti-AML activity, most notably the A extracts from the Anabaena sp. M4, M27, M30, 
M44 and M45 (Figure 1), were previously found to lack activity against normal primary hepatocytes 
(see [17]). We therefore conclude that marine benthic cyanobacteria are not only a rich source of cell 
death inducing activity, but also contain apoptogens selective for AML cells.  
Figure 1. Induction of leukemia cell death by cyanobacterial extracts. Rat acute myeloid 
leukemia  cells  were  incubated  with  aqueous  (A),  aqueous  methanol  (B)  or  
methanol-dichloromethane  (C)  cyanobacterial  extracts  at  a  concentration  of  4  mg  DW 
biomass/mL for 18 hours before being fixed in 2% buffered formaldehyde (pH 7.4) with 
the  DNA-dye  Hoechst  33342.  Cell  death  was  assessed  by  microscopic  assessment  of 
surface and nuclear morphology. The results are the mean, n = 3. Vehicle treated cells had 
less than 2% apoptosis.  




2.2. Modulation of blood platelet activity by cyanobacterial extracts 
Thrombocyte function is critical in leukemia, which is characterized by platelet deficiency due both 
to thrombocytopenia and thromboembolic complications [8,24,25]. Moreover, treatment of leukemia 
with cytotoxic drugs may change platelet function in vivo (reviewed in [26]). We therefore studied if 
any  of  the  cyanobacterial  extracts  contained  blood  platelet  activating  activity  that  could  limit 
usefulness  as  anti-AML  agents.  Interestingly,  we  found  that  a  high  proportion  of  the  C  extracts 
contained blood platelet activators (Figure 2). Of more importance for the present study is that the 
antileukemic A extracts of M27, M30, M44 and M45, unlike the anticancer drug daunorubicin [26], 
lacked platelet-modulating activity (Figure 2A). 
Figure  2.  Modulation  of  blood  platelet  activity  by  cyanobacterial  extracts.  Gel-filtered 
human  blood  platelets  were incubated for 30  min with  PE-conjugated anti-CD62P  and 
aqueous  (A),  aqueous  methanol  (B)  or  methanol-dichloromethane  (C)  cyanobacterial 
extracts,  4  mg  DW  biomass/mL,  or  thrombin  receptor  agonist  peptide  (TRAP).  The 
platelets were then fixed and analyzed for externalization of CD62P by flow cytometry. 
The results are mean and SEM, n = 3–9. 
 
2.3. Drug-relevant features of the apoptogens in cyanobacteria M27, M30 and M44 
Although the IPC-81 AML cells used in the primary screen respond in a clinically relevant way to 




IPC-81 apoptogens induce death in other relevant AML cell lines. In this respect, the aqueous extracts 
from M27, M30 and M44 were overall more efficient than those from M45 and M4 (not shown). M27, 
M30 and M44 induced apoptosis rapidly in human HL-60 AML cells (Figure 3), even compared to a 
higher-than-therapeutic concentration of daunorubicin in these cells ([27], data not shown). The high 
potency and rapid action of M27, M30 and M44 towards the leukemia cells are advantageous for in 
vivo therapy, since there will be a shorter burst of the drug, thus allowing less time for the formation of 
potentially generally harmful metabolites of the drug. For these reasons, the aqueous extracts from 
M27, M30 and M44 were selected for further studies. 
Figure 3. Cyanobacterial extracts induced rapid apoptosis in HL-60 acute myeloid leukemia 
cells. HL-60 cells were incubated without (Ctr) or with 4 mg DW biomass/mL of aqueous 
cyanobacterial extracts for 30, 60 or 120 min. Cells were fixed and stained, and apoptosis 
assessed as described in the legend to Figure 1. The results are mean and SEM, n = 3. 
 
Cell death induced by M27, M30 or M44 had the morphological hallmarks of apoptosis, such as 
chromatin  condensation,  nuclear  fragmentation,  surface  budding  and  shedding  of  apoptotic  bodies 
(Figure 4A-D). The apoptotic phenotype was as striking as the one observed in cells incubated with the 
benchmark anti-AML drug daunorubicin (Figure 4E).  
Cells overexpressing Bcl-2 are resistant towards stimuli leading to mitochondrial instability with 
release of pro-apoptotic proteins [28]. IPC-81 AML cells with enforced expression of Bcl-2 [29] were 
resistant towards apoptosis induced by either daunorubicin or by the apoptogens in M27, M30 or M44 
(not shown). This indicates that like daunorubicin, the cyanobacterial apoptogens signaled through the 
mitochondrial cell death pathway. Significant differences were discovered, however, between the AML 
apoptogens with respect to the involvement of caspase dependent cell death pathways. The apoptosis 
induced by activation of the cAMP-dependent protein kinase by a cAMP analogue was completely 
abrogated by the caspase inhibitor zVADfmk, whereas apoptosis induced by M30 or M44 appeared to 
be caspase independent and apoptosis induced by daunorubicin or M27 was partially inhibited by the 




Figure  4. Apoptotic morphology induced by cyanobacterial extracts in AML cells. Rat 
leukemia cells (A: control) were added the aqueous extract of the cyanobacterial strain M27 
(B), M30 (C), M44 (D) or 50 nM daunorubicin (DNR, E) as described in the legend to 
Figure 1, and photomicrographs were taken using differential interference contrast (upper) 
and UV (lower). Bar represent 10 m.  
 
Figure 5. Involvement of caspases and LEDGF/p75 in apoptosis induced by cyanobacterial 
extracts. (A) Rat acute myeloid leukemia cells were incubated with or without 50M of the  
pan-caspase inhibitor zVAD for 30 min before addition of 200 nM daunorubicin (DNR),  
25 M 8-chlorophenylthio-cAMP (8-CPT), or 4 mg DW biomass/mL of cyanobacterial 
extracts. The experiments were stopped after 7 h of incubation. zVAD-fmk alone induced 
less than 3% apoptosis during the 7.5 h of incubation. (B) Rat acute myeloid leukemia cells 
with or without enforced expression of the survival factor LEDGF/p75 (black and white 
columns, respectively) were incubated with various concentrations of known apoptosis-
inducers or cyanobacterial extracts for 18 hours. The cells were fixed and stained, and 
apoptosis assessed as described in the legend to Figure 1. The results are mean and SEM,  
n = 3–6.  
 
Drug  resistance  is  the  major  cause  of  therapeutic  failure  in  AML  [9,10].  We  have  found  that 




LEDGF/p75  is  a  survival  factor  reported  to  inhibit  a  caspase-independent  lysosomal  cell  death  
pathway [13]. As previously observed [11], we found, that IPC-81 cells with enforced expression of 
LEDGF/p75 were less sensitive towards apoptosis induced by either cAMP analog or daunorubicin. In 
contrast,  such  cells  had  intact  sensitivity  towards  M44,  and  even  showed  enhanced  apoptosis, 
compared to wild-type cells, at low M44 concentrations (Figure 5B). M27 and M30 induced a response 
intermediate between M44 and daunorubicin. They resembled M44 by tending to enhance apoptosis in 
the LEDGF/p75 overexpressing cells at low concentrations, but were like daunorubicin less efficient 
against these cells at high concentrations (Figure 5B). We conclude that M44 and to a lesser extent 
M27 and M30 had better ability than daunorubicin to circumvent the chemoresistance provided by 
LEDGF/p75.  
Figure  6.  Cyanobacterial  extracts  induce  a  synergistic  apoptotic  response  with 
daunorubicin  in  acute  myeloid  leukemia  cells,  but  not  in  cardiomyoblasts.  Rat  acute 
myeloid  leukemia  cells  without  (A)  or  with  enforced  expression  of  the  survival  factor 
LEDGF/p75 (B), or cardiomyoblasts (C), were incubated for 18 hours with cyanobacterial 
extracts  alone  or  in  combination  with  daunorubicin  (DNR)  (white  and  black  columns, 
respectively)  before  fixation,  staining  and  assessment  of  apoptosis  as  described  in  the 
legend to Figure 1. The results are mean and SEM, n = 3. 




Since  M44,  and  to  a  lesser  extent  M27  and  M30,  differed  from  daunorubicin  in  cell  death 
mechanism and in efficiency against LEDGF/p75 overexpressing cells, they could be useful adjuncts to 
daunorubicin. In fact, all three synergized strongly with daunorubicin to induce apoptosis whether the 
AML cells had enforced expression of LEGDF/p75 or not (Figure 6A and B). This suggests that the 
cyanobacterial  apoptogens  have  potential  to  enhance  the  efficiency  of  daunorubicin,  also  in  cells 
expressing the chemoresistance-associated LEDGF/p75.  
A major limitation for drugs and drug combinations is unwanted side effects [10,16]. Since the 
major side effect of anthracyclines in cancer therapy is cardiotoxicity [8,16], we studied whether any of 
the  cyanobacterial  activities  had  intrinsic  cardiomyoblast  toxicity  or  enhanced  the  toxicity  of 
daunorubicin in such cells. The intrinsic ability of M27, M30 or M44 to induce cardiomyoblast death 
was far lower than for the AML cells, confirming their AML selectivity (Figure 6 and data not shown). 
Furthermore, at concentrations effective against AML cells, M27, M30 and M44 failed to enhance the 
daunorubicin  toxicity  towards  cardiomyoblasts.  On  the  contrary,  M44  significantly  reduced  the 
daunorubicin toxicity (Figure 6C).  
3. Discussion 
We have previously reported that cyanobacteria from temperate environments are a rich source of 
bioactivities [17–21]. In the present study we have shown that culturable marine benthic cyanobacteria 
from temperate environments produce bioactive compounds with potential as anticancer drugs. In line 
with previous studies [17,20,21], we found that cyanobacteria of the genera Anabaena most frequently 
contained bioactivities. 
Based on the initial screen we focused on the five aqueous cyanobacterial extracts, which induced 
apoptosis preferentially in AML cells (Figure 1), whereas normal primary hepatocytes remained viable 
[17]. Three of them (M30, M27 and M44) induced apoptosis in human AML cells in less than two 
hours, suggesting an efficient and direct cell death pathway. The rapid action is an advantage from a 
pharmaceutical standpoint, especially if the active compounds should have short biological half-life, 
whether due to renal excretion or metabolic conversion to inactive metabolites. 
As based on defining morphological criteria [30], the cyanobacteria induced classical apoptotic cell 
death (Figure 4). The death depended little or not at all on caspases (Figure 5A). From a drug point of 
view it is interesting that the apoptogenic activity in M27, M30 and M44 was high also against AML 
cells with enforced expression of LEDGF/p75 (Figure 6B), which is upregulated in most cases of 
chemotherapy-resistant AML [11]. 
It is recommended that new AML treatment strategies should consist of drug combinations [10] to 
cover  a  broader  range  of  cell  death  pathways,  since  acquired  apoptotic  resistance  caused  by 
deregulation  of  death  signaling  mechanisms  is  a  common  feature  in  malignant  cells  [31].  If  two 
compounds act synergistically their combination may allow lower doses of each and thereby decrease 
the toxicity as compared to monotherapy. We found that the combination of a moderate concentration 
of  the  anticancer  drug  daunorubicin  with  M27,  M30  or  M44  (Figure  6A)  induced  a  synergistic 
apoptotic response in AML cells (Figure 6A) and chemoresistant AML cells with enforced expression 
of LEDGF/p75 (Figure 6B). This means that these cyanobacterial apoptogens have the ability to greatly 




cardiotoxicity [8,16] and it is crucial that anticancer drug combinations do not escalate this cardiotoxic 
effect.  Notably,  neither  of  the  cyanobacterial  extracts  synergized  with  daunorubicin  causing 
cardiomyoblast  toxicity  (Figure  6C).  In  fact,  M44  appeared  to  protect  the  cardiac  cells  against 
daunorubicin-induced  toxicity.  These  properties  of  the  cyanobacterial  apoptogens  are  important  in 
AML  drug  development,  since  less  toxic  treatment  strategies  as  well  as  strategies  to  circumvent 
chemoresistance are needed [10].  
We  found  that  the  majority  of  the  anti-AML-activity  resided  in  the  aqueous  extracts.  This  is 
promising since high aqueous solubility is considered pharmacokinetically favorable [32,33]. On the 
other hand, highly water-soluble compounds can be difficult to isolate using high performance liquid 
chromatography,  as  illustrated  for  the  death-inducing  activity  of  M44  (supplementary  Figure  S2). 
Recent advances in scaled-up counter-current chromatography [34,35] and further improvements of 
large scale culturing of benthic cyanobacteria will presumably pave the way for more satisfactory large 
scale  isolation  of  the  highly  polar  anticancer  compounds  from  marine  benthic  and  other  [20] 
cyanobacteria. 
4. Conclusions  
In summary, this study shows that culturable marine benthic cyanobacteria are a promising source of 
bioactive compounds with potential as anticancer drug candidates or lead compounds. The observation 
that compounds from benthic cyanobacteria combined with daunorubicin induce a synergistic apoptotic 
response in AML cells, but not in normal cardiomyoblasts supports this conclusion. The apoptogens 
contained in these marine benthic cyanobacteria, coupled to current progress in scaled-up culturing and 
chemical purification, indicate that this hitherto underexploited niche of cyanobacteria is an exploitable 
source for novel anticancer drug candidates.  
5. Experimental Section 
5.1. Materials 
Dichloromethane,  dimethylsulfoxide  (DMSO),  Hoechst  33342,  penicillin/streptomycin,  
8-chlorophenylthio-cAMP and daunorubicin were from Sigma-Aldrich (St. Louis, USA). Methanol and 
formaldehyde were from VWR (West Chester, USA). Dulbecco’s Modified Eagle Medium (DMEM), 
Fetal Calf Serum (FCS) and Horse Serum (HS) were supplied by EuroClone Life Sciences Division 
(Milan,  Italy).  RPMI  1640  Medium  (Gibcoinvitrogen  cell  culture)  was  from  Invitrogen  AS 
(Carlsbad,  USA).  PE-conjugated  anti-human  CD62P  antibody  (CAT.  #348107)  was  from  Becton 
Dickinson Biosciences (San Jose, USA). Thrombin receptor agonist peptide (TRAP, SFLLRN) was 
from  the  Biotechnology  centre  of  Oslo  (Oslo,  Norway).  Z-val-ala-DL-asp-fluoromethylketone  
(zVAD-fmk) was from Alexis Biochemicals (San Diego, USA). 
5.2. Isolation and cultivation of cyanobacterial strains 
The cyanobacterial strains used in this study [17] were collected from sediment, sand, surface of 
stones, rocks, water plants, macroalgae, mussels or molluscs from the Baltic Sea at Porkkala (Gulf of 




Calothrix or Cyanothece (see supplementary material: Figure S1 and Table S1) and mass cultivated as 
previously  described  [17].  Cyanobacterial  cells  were  cultured  for  20–60  days  before  they  were 
harvested by centrifugation and freeze dried.  
5.3. Sequential extraction of cyanobacterial biomass 
Extraction of cyanobacterial biomass was performed as described by Herfindal et al. [17]. In brief, 
freeze-dried  cyanobacterial  biomass  was  first  extracted  in  water,  followed  by  extraction  in  70% 
aqueous methanol and finally 1:1 (v/v) methanol:dichloromethane. The extracts were then dried in a 
centrifugal  vacuum  concentrator  (Savant  SpeedVacAES1010)  and  resuspended  in  either  0.2  mL 
water (aqueous; A extract), 0.05 mL water (70% aqueous methanol; B extract) or 0.05 mL DMSO 
(methanol:dichloromethane; C extract). 
5.4. Maintenance of cell lines, experimental conditions and determination of cell death 
The  rat  promyeloid  leukemia  cell  lines  IPC-81  wild-type  cells  [22],  and  IPC-81  with  enforced 
expression of LEDGF/p75 [11] or Bcl-2 [29], were cultured in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 50 U/mL of penicillin and 0.05 mg/mL streptomycin and 10% (v/v) heat 
inactivated horse serum. The rat cardiomyoblastic cell line H9c2 (ATCC: CRL-1446) was cultured in 
DMEM with antibiotics as described above but enriched with 10% (v/v) heat inactivated fetal calf 
serum.  When  the  cells  reached  80%  confluence,  they  were  detached  by  mild  trypsin  treatment  
(0.33 mg/mL trypsin for 5 min at 37 C), washed and reseeded in fresh medium to 25% confluence. 
The human myeloid leukemia cell line HL-60 (ATCC: CCL-240) was cultured in RPMI medium with 
antibiotics as described above and enriched with 10% (v/v) heat inactivated fetal calf serum. All cells 
were cultured at 37 C in a humid atmosphere of 5% CO2. 
For assays of cell death, the suspension cells were centrifuged at 160 ×  g for 4 min, resuspended in 
fresh  medium  and  1.5  ×   10
4  cells  were  seeded  in  0.1  mL  in  a  96-well  tissue  culture  plate.  The 
cardiomyoblasts were detached, centrifuged, and 2000 cells were seeded in each well of a 96-well 
tissue culture plates 24 hours before start of the cell death assays. The experiments were stopped by 
addition of 0.1 mL PBS containing 4% formaldehyde (pH 7.4) and 0.01 mg/mL of the DNA specific 
fluorescent  dye  Hoechst  33342.  Apoptosis  was  scored  by  differential  interference  contrast  and 
fluorescence microscopy (Axiovert 35M, Zeiss) as previously described [37]. Untreated cells or cells 
added vehicle exhibited a viability of more than 97%.  
5.5. Isolation, incubation and flow cytometry analysis of human blood platelets. 
Isolation of human blood platelets was from fresh whole blood, as previously described [38,39]. In 
brief, platelet rich plasma obtained by centrifugation of whole blood was gel filtered and platelets 
eluted into a calcium-free Tyrode’s buffer containing glucose and bovine serum albumin at pH 7.3.  
The gel-filtered human blood platelets (3.5 ×  10
7 per sample) were incubated under non-stirring 
conditions for 30 min with cyanobacterial extract or Thrombin Receptor Agonist Peptide SFLLRN 
(TRAP), PBS (5 μL) and anti-CD62PE (0.24 g/mL) in a total volume of 25 μL. The platelets were 




was carried out using a FACSort flow cytometer as described by Selheim et al. [40]. Ten thousand 
platelets,  identified  by  size  (light  scatter  gating),  were  analyzed  for  CD62PE  fluorescence  
per sample. 
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